Indoco Remedies announces receipt of Approval of its ANDA for Succinylcholine Chloride Injection USP 200 mg / 10 ml (20 mg / ml) Multi-dose vial, therapeutically equivalent to the Reference Listed Drug (RLD) Quelicin Injection of Hospira, Inc.

Succinylcholine Chloride Injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The US market size of Succinylcholine Chloride Injection is of 72 million USD (6 million vials), as per IMS data for the year ending March, 2020.

The product is being used for some patients infected with Corona virus (COVID-19).

Commenting on this positive outcome, Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. said, "The receipt of this USFDA approval, in a record time of just 4 months from the date of filing ANDA, is very encouraging. It brings an enormous opportunity to Indoco to serve the patients in these trying times."

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.209.8 as compared to the previous close of Rs. 215.8. The total number of shares traded during the day was 674 in over 110 trades.

The stock hit an intraday high of Rs. 216.45 and intraday low of 208.1. The net turnover during the day was Rs. 142423.

Source: Equity Bulls